FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Free Newsletter

About | View Sample | Privacy

Vax for range of cancers may be available in 5 years

Tools

A vaccine that has shown to be effective against breast, bowel and cervical cancers is being tested on some patients and may be available in about five years. The vaccine, which is being developed by Celldex Therapeutics (NASDAQ: CLDX) and Middlesex University, tells the immune system to destroy a hormone called hCG. The hormone is normally present only during pregnancy, but is also made by about half of patients who have bladder and pancreatic cancer, as well as some people who have breast, bowel, ovarian and cervical tumors, NY Daily News reports.

Animal tests have already demonstrated 'extremely good' results and preliminary trials on people show it to be safe, the U.K.'s Daily Mail notes. The jab is now being given to 60 patients with newly diagnosed with bladder cancer.

Cancer Council South Australia chief executive Professor Brenda Wilson says the council would follow the trial's results. "Although this is a promising approach, there's a long way to go before we can definitively say that this vaccine will help save lives," she told Aidelaidenow.

- see the Daily Mail report
- get more from Adelaidenow
- read more from the TopNews blog
- get more from the NY Daily News

Related Articles:
Breast cancer vaccine success stirs controversy
Hunt for the next big cancer vaccine fraught with peril
Researchers see cancer vaccine revolution on the horizon


SHARE
WITH:
Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FierceVaccines Email Newsletter:
Be the first to comment
More stories about Celldex Therapeutics   cancer vaccine  

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.